Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

Investors Business Daily

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

The Conversation

Dow Jones Futures Rise After Market Rallies On Microsoft AI Push; Netflix, Tesla Earnings On Tap

Microsoft AI pricing fueled the Nasdaq, which is increasingly extended. Netflix and Tesla earnings loom.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Microsoft, Eli Lilly Bolster Stock Market Upside; This Sector Is Smashing The Dow Jones Industrial Average's Performance

ARCB also is trying to storm past a cup with handle that shows a 101.49 buy point.

Investors Business Daily

IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout

Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears "very competitive" with Biogen's.

Investors Business Daily

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

StockNews.com

New drug found to slow Alzheimer’s hailed as turning point

Donanemab has been found to slow down the disease in a clinical trial.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

The Independent UK

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

Evening Standard

Experts urge health regulators to approve ‘turning point’ dementia drugs

Exclusive: As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

The Guardian - UK

What impact will Alzheimer’s drug donanemab have?

While it is not a cure, proof that drugs can alter course of disease is regarded as significant triumph

The Guardian - UK

How Weight-Loss Behemoth Lilly Is Trying To Leapfrog Chief Rival Novo

Eli Lilly stock jumped Friday after unveiling a nearly $2 billion takeover that could bolster its efforts among weight-loss drugs.

Investors Business Daily

S&P 500, Nasdaq Hit Fresh 52-Week Highs As Inflation Fears Ebb; Salesforce, Delta, JPMorgan In Focus: Weekly Review

The S&P 500 and Nasdaq led a strong market rally this week as inflation fears wane. Salesforce, Delta Air Lines, JPMorgan were key newsmakers

Investors Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

Fortune

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

Get all your
news in one place.

100’s of premium titles.
One news app.

Zenger

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Investors Business Daily

Stock Market Rebounds Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review

The market rally had a strong week, with the major indexes rebounding toward 2023 highs and many stocks flashing buy signals.

Investors Business Daily

Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 400%

Eli Lilly said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics, and the biotech stock skyrocketed.

StockNews.com

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

Investors Business Daily

Why Lilly's Obesity Treatment Update Sent Novo, Madrigal And Viking Shares Diving

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Nottingham Post

Weight loss jab rejected for NHS use over effectiveness concerns - despite positive trials

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

Wales Online

Weight loss injection rejected for NHS use over effectiveness concerns

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

1 … 17 18 19 20

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations